Corbion N.V. (AMS:CRBN)
Netherlands flag Netherlands · Delayed Price · Currency is EUR
26.38
-0.18 (-0.68%)
Nov 16, 2026, 5:35 PM CET
← View all transcripts

Status update

Nov 11, 2026

Summary

BRIGHT 2030 innovation aims to support 3%-6% annual sales growth and an 18% adjusted EBITDA margin by 2028. Innovation launched in the period is expected to add 1.5%-2% annual growth over the 2025 revenue baseline, with digital and AI supporting productivity gains.

Alex Sokolowski
VP of Investor Relations, Corbion

Good morning, and welcome to Corbion's Innovation Webcast 2026. I am Alex Sokolowski, Head of Investor Relations, and let me introduce our speaker this morning, Dr. Yves Boland. Dr. Boland has been Corbion's Chief Technology Officer and member of the executive committee since 2025. Prior to joining Corbion, he served as Vice President of Technical and Business Development for EMEA at Tate & Lyle.

Before that, Yves spent over 13 years at CP Kelco, holding various senior leadership roles, including Senior Vice President of Global Innovation and Senior Director of Innovation Discovery and Business Development. Prior to joining CP Kelco, he worked at Thermphos International and Procter & Gamble. Yves brings a wealth of experience in innovation and business development with a strong focus on creating value through cutting-edge technology and market insights.

His extensive background in the food and beverage sector equips him with a unique perspective on driving performance and fostering collaboration across teams. Without further ado, Yves.

Yves Boland
CTO, Corbion

Thank you, Alex. Today, I am going to talk about how Corbion's innovation platform support our BRIGHT 2030 strategy and how it is a key growth vector for Corbion. Before going there, it is useful to look back on what we said during last year's Capital Markets Day. Our BRIGHT 2030 strategy positioned Corbion as a sustainable specialty food ingredient company focused on natural preservation and nutrition by leveraging our backbone in fermentation technologies and food solution expertise in order to offer differentiated, natural, and label-friendly ingredients.

We indicated the three following targets for the period 2026-2028. We focus today on sales and EBITDA. First, 3%-6% sales growth per annum. Second, an adjusted EBITDA margin of 18% by 2028, and accumulated cash flow of EUR 270 million over the 2026-2028 period.

Corbion has historically, depending on the market we served, either been deeply rooted in biotechnologies or be strong at integrating solutions and providing ready-to-use solution for customer. With BRIGHT 2030, our purpose, preserving what matters, remain more relevant than ever. However, the recentering of our strategy on food and nutrition, with this refocus, we can become a stronger bioscience-backed solution provider across our strategic segments.

We are proud and committed to a bioscience leadership. We are reinforcing our applied science capabilities beyond niche areas of expertise to become a technology-focused, backward-integrated solution provider and an innovation partner to provide greater value to our customer and theirs. While our investment level in R&D is in line with our peers, around 3.4% of revenue or around EUR 43 million in 2025, our innovation and solution development has had a significant positive impact.

A bit more than one-fifth of our revenue comes from product and solution which are either new or produced by new and more efficient technologies. During the last strategic period, efforts have been leaning more toward new and more efficient processes, which have both reinforced our competitiveness and make our business more sustainable from both a financial and carbon and water footprint point of view.

During this strategic period, we will accelerate on revenue from innovation while maintaining contribution to efficiency programs. We have strong foundations, and we can get more from it through focus, expansion, and acceleration to create greater value. Focus is about concentrating resources on the opportunities when Corbion can create the greatest value. Expand is about building on our application capabilities and complementing internal innovation with external opportunities.

Accelerate is about increasing innovation speed and productivity through process excellence, digital data, and AI. Those three levers will create greater value for Corbion. Before going into more details of these three pillars, focus, expand, accelerate, let's have a look at what is shaping the food and nutrition space, which is continuously evolving with some long-lasting trends and other which are accelerating.

Healthy and safe food. Consumers aspire to eat healthily or what is perceived as healthy food. This aspiration translate into a continuous push for short ingredient list with label-friendly ingredients and ingredient associated with health benefits, such as fiber for gut health or protein for muscle health.

Attention to food safety is also a continuous theme with increasingly stringent regulation and consumer desire to avoid synthetic or artificial preservative, or artificial ingredient in general. Recent reduction in nitrite and nitrate permitted levels in the European Union and phasing out of bromate in California are two relevant example which create opportunities for Corbion.

Inflation of food prices, particularly since the COVID pandemic, has presented a challenge for both consumer and the food industry. It means, among other things, that label-friendly ingredient lists must be realized at limited or no premium for consumers. This creates an opportunity, as Corbion can tailor ingredients to have dual functionality, for instance.

This being said, a K-shaped economy also sustains the growth of a premium segment where innovation can still command a premium. Reduction of food waste and spoilage has both a way to mitigate cost and sustain our food chain. This remains a topic of interest, where Corbion plays a key role with natural preservation. The adoption of GLP-1s and other weight control drugs are driving demand for increased nutrition from fewer calories. We see example in protein, fiber, and other nutrient-fortified foods.

Interestingly, these needs closely match the need of an aging population and of sport nutrition, which is also growing in popularity. Finally, food producers keep on reporting the need for ever-fast idea-to-launch cycles. It materializes in shorter turnaround time on briefs and an increasing reliance on co-packers to have a flexible supply chain. Now let's have a look at our three pillars, starting with focus.

Focus on winning big. We have been shifting resources and increasing our agility to, one, reduce our time to market or time to deliver a proof of concept in the hand of customers, and second, to reallocate our effort toward either incremental innovation, which delivers short-term value, or big, ambitious opportunity, which can unlock significant growth potential.

By being more selective, relentlessly pursuing value delivery for our customer, and being able to get fast proof of concept, we were able to increase speed through our innovation funnel by a factor of four, so 4x faster. We are also increasing our investment in innovation in a disciplined manner, with a focus on one hand on application labs and product pilot to better serve our customer, and on the other hand, on open innovation.

We plan to invest at or above revenue growth to increase resource allocation toward R&D throughout the strategic period. A capability we are and we will keep on focusing on is our biomanufacturing leadership. Corbion's technology stack allows us to do two things simultaneously. One, bring new product to the market, and second, maintain cost leadership. So, from strain to factory is one of our strengths.

We have strain development capabilities for non-GMO and GMO strains. We have fermentation development optimization, where the magic happens, turning bio-based carbon source such as starch or sugar into value-added ingredients. We have downstream processing, where efficient separation, purification, concentration, and further processing steps allow the transformation of fermentation broth into finished product.

Having these capabilities at laboratory, pilot, and full scale is what allow us to bring new product to the market and stay competitive. One key capability is having pilot plants which are actually scaled-down factories to ensure efficient scale-up. This is often the missing link when moving from lab to factory, and we have this capability both in the United States and Europe. What does our focus on biomanufacturing leadership do for us?

It allows our team to continuously improve carbon conversion, reduce nutrient consumption, shorten fermentation cycles, and minimizing unwanted biomass formation, the biomass being all the microorganisms we first need to grow before making them produce the target ingredient.

To give an idea of the importance of this improvement, let's have a look at a theoretical model, a system typical for precision fermentation, where the fermentation time is seven days and about 25%, so a quarter of the carbon source is being converted into the target ingredient.

The rest, again, is used for growth and general metabolism of the biomass. Reducing fermentation time by two days and lowering biomass generation by 30% create, in this case, direct benefits in raw material consumption, asset utilization, energy consumption, and manufacturing cost, resulting in an about 20% reduction, a fifth reduction in the production cost.

It's about using less raw material to get the same output in a shorter period of time. But fermentation is only one part of the equation. In many bioprocesses, downstream processing, or DSP, can account for a substantial share of total production cost. That's why we focus not only on fermentation yield, but also on DSP yield, because every kilogram or pound lost during recovery, separation, or purification increases the cost of the final product.

Our economic models explicitly integrate fermentation KPIs together with DSP yield, substrate utilization, purification cost, and recovery losses, enabling us to identify the largest value levers early in development. We have developed our liquid suspension in omega-3 DHA production to minimize downstream processing losses while retaining nutrition protein from the biomass in the finished feed product. This is a good example of efficient redesign of DSP to maximize value along the value chain.

Another example is the gypsum-free recovery process for a circular lactic acid factory in Thailand. These capabilities become increasingly important as fermentation expands its scope of addressable ingredients. The winners will not necessarily be those who can make a molecule in the laboratory. The winners will be those who can produce it at industrial scale with superior economics.

Corbion's combination of fermentation know-how, downstream processing expertise, and scale-up experience give us a strong foundation to maintain cost leadership while building the next generation of fermentation-enabled businesses. Our second pillar is expand, where we look at how to extend the value and reach of our existing capabilities. In the food and nutrition industry, application refers more to the D in R&D, so the development side. It is about translating the science behind ingredients into tasty and healthy food recipes.

It is a pivotal capability that allows us to engage with customers, understand their needs, and come back, for instance, with a low-salt, shelf-stable soy sauce that tastes as great as the full-salt version and has retained its savory umami notes without all the sodium. Comparison with peers indicates that forward integration into solutions can translate into increased profitability, especially when anchored with differentiated ingredients.

Actually, starting with the value being delivered to customers is an even better way to grow profitable businesses, develop successful innovation, and drive customer satisfaction. That is why, building on BRIGHT 2030 ambition as a sustainable specialty food company, we are further evolving into a bioscience-backed solution provider. This step will allow us to capture more value versus being just an ingredient supplier.

Providing ready-to-use solutions, ready to be marketed, is valuable for food and beverage manufacturers, and capturing a share of this value typically allows higher margins. For Corbion, this means going beyond supplying individual ingredients. We develop concepts and ready-to-use recipes that combine one or more Corbion ingredients with the supporting nutritional and sensory data, and in some cases, consumer likability scores.

This gives customers a solution that is much closer to implementation in their own production environment, rather than an ingredient they still need to formulate into an end product by themselves. Continuing on the expand pillar, we think the trends shaping food and nutrition increasingly play to Corbion's strengths. Consumers want healthier, safer, and more sustainable food, while food manufacturers need affordable, label-friendly solutions and faster innovation cycles.

Corbion is uniquely positioned at the intersection of these strengths through its fermentation platform, preservation expertise, microbiology capabilities, predictive modeling tools, and deep application know-how. Our role is increasingly not just to supply ingredients, but to help our customers bring better products to market faster, with lower risk and greater consumer relevance.

From an R&D standpoint, we are broadening our food and nutrition-related product line and expanding into new ingredient categories, providing sought-after benefits in our key markets. We are also focusing on bioscience leadership to develop the next blockbuster ingredient while maintaining cost leadership. This capability gives us the foundation not only to improve what we do today, but also build what comes next. The question is not simply what our next product will be, but it is more about where can we build the next scalable growth platform.

Omega-3 DHA became a major category because growing consumer demand eventually collided with limitation in traditional supply. That created an opportunity for technology such as algal fermentation to provide more scalable, traceable, and sustainable source. We believe similar opportunities will continue to emerge in an increasingly resource-constrained world. Many supply chains face pressure from land availability, climate volatility, biodiversity concern, geopolitical disruption, and growing demand for transparency and traceability.

At the same time, consumers and regulators continue to raise expectation around health, safety, sustainability, and ingredient provenance of their food. Our innovation strategy is therefore focused on identifying ingredient where growing market needs and scalable technology intersect with supply constraint. When the market needs more protein, specialty lipid, bioactive, or functional ingredient than traditional source can reliably provide, alternative production routes become attractive.

Cellular agriculture, where biological systems such as microorganism or cells are used to produce ingredients through fermentation or other processes. It is particularly powerful because it can decouple supply from agricultural, marine, or geographically constrained source while improving consistency and traceability. Expanding to the next blockbuster area, we are working on next-generation natural preservation, sustainable lipids, antioxidant, and exploring peptide and protein for food.

Our next-generation preservation, on that pillar, we are expanding in food ferment with upcoming launches to bring label-friendly preservation to prepared food based on consumer-preferred feedstock and labeling, addressing a market of about EUR 250 million, which is expected to grow at a 7% compound annual rate. We are also going beyond just pathogen and spore growth inhibition to ingredient with biocidal activities, which means they actually kill germs.

Here, we focus on Listeria control to offer solutions to comply with tightening regulation, addressing the EUR 1.5 billion Listeria control market, which is also growing double digits per year. In sustainable lipids, we are expanding our omega-3 portfolio, as we communicated during the Capital Markets Day. We are also now working on structured lipids, which provide both structure and texture to a variety of foods.

We are working on our first ingredient now, and over time, we target the development of a toolbox, which will provide a range of texture and mouth feel from our developed solution. This is a EUR 2 billion niche market in the broader EUR 15 billion-EUR 20 billion lipid market. The first building blocks of our toolbox address an addressable market of around EUR 300 million-EUR 500 million.

Later in the presentation, I will show an example of an antioxidant developed by open innovation, because antioxidant, especially when produced through fermentation, are at the intersection of the key strategic area for Corbion and of our capabilities. They typically provide health benefit, shelf life extension, and preservation. The global antiox market for human nutrition alone is worth about EUR 3 billion and is being dominated by plant extract.

Fermentation-based antiox, such as carotenoid, represent a market of about EUR 300 million, which we plan to step into. Finally, we are exploring precision fermentation-related opportunities in peptide and in protein specialized nutrition. We believe we have a right to win in this space, thanks to our technology stack and our market access. We are, however, carefully mapping the landscape, the technology readiness, and the capabilities required to win before committing fully to this area.

Most sought-after protein in this space of nutrition typically represent a few hundred million euro opportunity per protein, and they typically grow by double digits per year. The world is continuously changing, and our customer requires shorter time from brief to launch. Investment in application, agile innovation processes, and speeding up of internal development are not enough to keep pace.

Open innovation is and will keep on playing an increasingly important role in Corbion innovation strategy. A few days ago, we launched our NURTURE NEXT open innovation program. There are additional details on the website if you want to check it out. This program is a continuation and formalization of our open innovation effort. NURTURE NEXT is looking at partnering to bring the next nutrition or label-friendly preservation innovation to the market.

The team is also scouting for disruptive production technologies that could bring next-generation processes on how to produce Corbion existing core ingredients. Ultimately, the goal is to drive innovation from scouting to launch. Corbion is in a unique position to accelerate development, scale up, and market introduction of new ingredients and solution. We have advanced bioscience experience with best-in-class process development group and capabilities, such as pilot plant to de-risk and fast-track scale-up, where we have proven to be extremely strong.

We also have market knowledge and access to validate early assumption and concept, and later on launch innovative solution. When combined with the out-of-the-box thinking, agility, and drive of early-stage companies, our capabilities can unlock significant potential by accelerating and de-risking development. We have structured our NURTURE NEXT program around three pillars: technology and regulatory readiness, evaluation of inherent technology cost-efficacy, and an AI-powered market assessment.

We are focusing on technology readiness level, or TRL score, of six and above on the TRL scale. TRL 6 refers to when a fully-fledged prototype testing move outside of the strictly controlled laboratory environment into an environment that closely simulates real-world conditions. We are also looking at ingredient with a de-risked regulatory path and label-friendly naming.

These three elements, TRL 6 and above, clear regulatory path, and label-friendly naming, allow us to fast-track development and adoption. It may sound like looking for a needle in a haystack. However, we found that there are quite a few of these candidates in the high number of biotech startup we've been screening. Heavy investment across the biotech sector in the 2010s, followed by the post-pandemic hype around alternative protein and precision fermentation, has now given way to a more pragmatic focus on scaling proven technologies.

With capital becoming more selective, the conditions are increasingly right for balanced partnership between corporate and startup or scale-up. A great example coming from open innovation is astaxanthin, a project we first announced in August 2025. Astaxanthin is a natural antioxidant found in microalgae, which is both a recognized food supplement and gives salmon flesh its distinctive color.

Astaxanthin is positioned at the intersection of healthy aging, cognitive health, cardiovascular wellness, skin health, eye health, and sport nutrition, which makes it an attractive bioactive ingredient in today's nutraceutical market. The current mode of production for natural astaxanthin is highly inefficient, relying on open pond microalgae growth. Next to this, synthetic astaxanthin, made from petrochemicals, is also used in salmon feed to ensure the bright color of farm-raised fish.

It is, however, not permitted for organic salmon, where producer needs to use natural source of astaxanthin, like, for instance, from bacteria, which come with its own set of challenges. We are collaborating with the U.S.-based company KAS to bring an efficient microalgae-derived astaxanthin to market. First, to the food supplement market, and then, as scale is growth, to the aquaculture market to complement our omega-3 DHA offering. This is a good example of open innovation and next-gen ingredients such as antiox.

We have discussed the first two pillars of how we are transitioning to become a solution provider backward integrated in bioscience. First, focusing on winning big, and second, expanding through investment in application, open innovation, and portfolio extension. Now, let's have a look at the third pillar, accelerating with digital data and AI, but also open innovation.

Open innovation, we just discussed, is for sure playing a role in both expansion and acceleration. I will focus in this next section on digital data and AI. We have already introduced tools that helps us make better use of Corbion's decade of science, application knowledge, and data. For example, we are using an integrated large language model within Corbion IT environment that can retrieve and summarize knowledge from previous experiment and help draw conclusion from it.

This allow our team to develop and screen solution faster and avoid repeating experiment, particularly when addressing recurring or industry-wide customer challenges. But we have moved beyond individual productivity tools. Through capabilities such our data lab and data science group, we are increasingly using data and advanced modeling to improve our operation and optimize our processes.

One example I like very much is a crystallization step in one of our most successful product line. Changes earlier in the process to make it less energy intensive had affected the material entering the crystallizer, and it reduced its run rate. The challenge was complex, involving around 20 process variable and their interdependencies.

Instead of testing a large number of possible combination, more than 1 million for a non-guided approach that I would anyway not recommend, we used an advanced modeling and self-driving optimization approach based on something called Bayesian optimization. How does that work? In this case, the model learn from each experiment and use the result to determine the most valuable next experiment.

In this case, in 10 experimental run, we identify improved process setting that reduce process time and increase output by 110%, so more than double the output, with a high probability of being close to the optimal condition. By investing further in data science, machine learning, and AI, we expect to generate more high-quality data and become better at turning that data into action.

We expect this to reduce the number of experiment required to achieve a given outcome by at least 20%, while some advanced predictive model indicate potential for even greater reduction. Overall, we conservatively anticipate productivity gain in R&D between 10% and 20%. Combined with increased investment and a focus on winning big, our ambition is to double R&D contribution to new revenue while continuing to deliver on efficiency gain. What does greater value look like in practice?

We already have strong examples of innovation creating value for our customer and for Corbion. By bringing greater focus to where we can win, expanding how we turn our science into customer solutions, and accelerating how we innovate, we intend to create more of these successes, faster and at greater scale. Let's look at a few examples of what that means in practice. Sorry. Bit of a glitch.

Preservation is at the core of what we do, and a key differentiator for Corbion is that we don't rely solely on lab testing. We've built predictive preservation models that combine microbiology, food science, and product data to predict how factors such as acidity, water amount, temperature, oxygen, and preservative system interact in real food. Effective preservation depends on the food's composition, the specific spoilage organism or pathogen being targeted, and how well preservatives work individually, and even more important, together.

Understanding this interaction requires data. It's all about data. For every strain, you need the data on how it behaves. For every strain, you need the data on how it behaves, and how it behaves in a given food matrix, and how it responds to various parameters, preservative and combination of preservatives. The last part is important, as these are synergies which drive efficacy and cost-effectiveness, and having a portfolio really helps to bring the best solution to customer.

Corbion has strong models and tools from decades of data, and a pathogen and spoilage strain library. This library is a key competitive advantage of Corbion and contains more than 2.3 thousand strains from nearly 400 different species, mostly isolated from contaminated food. We keep on growing this library.

These models are validated in food application and delivered through practical tools that our teams and customer can use to accelerate formulation decisions. The result is faster development, lower testing burden, and greater confidence that food safety and shelf life targets will be achieved. The true value of these capabilities is demonstrated by customer adoption.

More than 150 individual customers used our preservation modeling tools in 2026 so far, helping translating scientific expertise into real-world commercial outcomes. The technology supports a sales pipeline exceeding EUR 100 million and has already contributed to more than EUR 25 million of new businesses since we started tracking a few months ago.

For us, this is a powerful example of how deep microbiology expertise, predictive science, and digital tools create value for customer while strengthening Corbion's competitive position. I will now discuss how our preservation know-how translates to raw salmon.

Raw salmon processors face a persistent risk from Listeria. Although contaminations are very rare, the consequences can be severe, including recalls, product losses, regulatory issues, and reputational damage. A single of such event resulted in publicly reported product recall loss in excess of EUR 30 million. Salmon processors are looking for practical ways to reduce Listeria risk at the harvesting station. This risk has been an enduring challenge for the industry.

However, Corbion has developed a patent-pending solution that combines one of our core preservatives with an innovative product sourced through open innovation. The solution enhances food safety, helping to lower the risk of recalls and product loss significantly. Importantly, it fits into existing salmon processing without slowing down operations. Developing the solution required expertise across microbiology, food safety, shelf life, and process validation.

We also conducted challenge testing, where Listeria is deliberately introduced under controlled conditions to test how effectively the solution works, followed then by trials in customer plants. Through this work, we validated that the solution remained effective for the required period while working within normal processing condition to not disturb customer operations.

This is a good example of what we mean by end-to-end innovation, combining our own expertise with open innovation, validating the solution in practice, and working closely with customer to move from an ingredient to a solution that can be implemented in their operations. The next example is about nutrition through food, which is driven by the trend for more nutrition in everyday food and protein fortification. A bakery manufacturer wanted to launch a sandwich bread containing 10 g of protein per serving while also supporting dairy-free, soy-free, and non-GMO claims.

The technical challenge was significant because adding large amount of protein typically create a tough dough, reduce loaf volume, produce a dense texture, and can introduce bitter off-flavor note that you absolutely don't want to have in bread. Corbion combined formulation expertise, plant trial support, and its pre-formulated protein solution to overcome these issues.

During scale-up, the team identified a low volume issue and corrected it without requiring broader formulation or process changes. The result was a high-protein bread concept that met the nutritional target while maintaining the eating quality and manufacturability expected in mainstream sandwich bread.

The solution is being implemented at various accounts, with sales already ramping up to beyond EUR 10 million per year. This is a good example where the combination of application expertise, formulation know-how, and plant scale validation help our customer to quickly develop and launch.

Let's now turn our attention to confectionery, which has been a success story for Corbion. I will speak about how Corbion innovation has accompanied the development of the fast-growing sour candy market on its evergreen journey of stronger sensation. It's a tale of sensory and preserving shelf life stability.

The candy market has been growing at an average of 3% per year, while the sour candy market seemed much faster grow around 15% per year. For most candy consumer, enjoyment actually decline once sourness exceed a certain threshold. But for sour candy enthusiasts, about 12%-13% of candy consumer, they continue to enjoy candy more as sourness increases beyond that point, a nd we have been developing acid sanding solution to match various sourness profile.

Our patented PURAC Powder product range enable a sour to extra sour eating experience. The extra sourness comes with extra challenges, as the coating stability is typically affected when stronger organic acid are used and overall acidity increases. One of Corbion innovation has been to deliver this extra sourness without the candy texture being affected or starting to become moist in the packaging, which impact the pleasant crunchiness from the sour candy eating experience.

This has been achieved by careful powder composition and powder particle design to balance acidity and release. This allowed delivering consumer-preferred sourness without compromising on shelf life or crunchiness. Actually, it even allow our customer to expand into market previously inaccessible to them due to stability challenge linked to tougher storage condition in warmer, higher humidity geographies.

An additional dimension of the sourness profile is how the sourness develop and dissipate. Consumer preference is to have quick burst of sourness with a sustained lingering sourness over time. Existing solution allow us to deliver the initial intense burst , thanks to particle size and proper design of the candy layers. There is still an opportunity to improve both long-lasting thoroughness and crunch.

This is where Corbion Next Innovation is focusing to deliver an even better solution for our customer, having the initial sensory data looking really promising. Today, we've seen how we keep on evolving our capabilities to become a bioscience-backed solution provider for natural food preservation and nutrition.

Focus, expand, and accelerate to create greater value is our approach. Focusing on areas where we have a right to win and win big. Expand our innovation reach through application, our NURTURE NEXT open innovation program, and new solution and platform. Accelerate thanks to digital data and AI, and targeted investment innovation and open innovation.

We intend to increase our innovation spend in a disciplined manner in line or ahead of revenue growth. We intend to grow our productivity by at least 10%-20% in order to double the innovation impact on new revenue generation while accelerating our effort towards innovative and data-led higher efficiency production process.

Based on our current risk-adjusted innovation pipeline, innovation being launched during the BRIGHT 2030 strategic period are expected to contribute to 1.5%-2% of growth per annum over the 2025 revenue baseline. Early-stage innovation and open innovation represent an additional upside on top of this 1.5%-2%. Improved margin from innovative product and solution, as well as more efficient ways of producing our ingredient, will contribute toward our 18% EBITDA margin ambition by 2028.

The risk-adjusted pipeline for efficiency gain from manufacturing innovation is, for instance, worth a bit north of 5% of a variable cost basis. It does not include other manufacturing gains from traditional continuous improvement or other initiative leveraging data and machine learning, for instance. All of those will contribute to better profitability and help mitigate inflation. I just want to reinforce our message one more time before taking your questions.

We are turning Corbion into a bioscience-backed solution provider for the food preservation and nutrition industry by focusing where we have a right to win and win big, expanding the reach and deployment of our innovation at customer, and expanding and accelerating thanks to our NURTURE NEXT open innovation program, and last but not least, accelerating thanks to our digital data and AI. Thank you all for your attention.

Alex Sokolowski
VP of Investor Relations, Corbion

Thank you, Yves. For those of you in the room, if you'd like to ask a question this morning, please wait for the mic, and please be sure to state your name and financial institution before proceeding to your questions. Also, just for the sake of time, please limit yourself to just two questions at a time. The mic can always come back. Anybody have a first question this morning?

Sebastian Bray
Analyst, Berenberg Bank

Thank you for your presentation. Sebastian Bray from Berenberg Bank. Can I ask about the cost of expanding the algal oil platform? Because of the innovations that you've mentioned, let's say the one it's easiest to draw a theme about is that Corbion has done well in algal oils and wants to broaden that platform into things like structured lipids. I think it's algal fermentation that makes the antiox.

Where is the company in its deliberations on whether to expand the algal capacity that it has in Brazil? What does it cost? Is this investment figure going to include some of the antiox and potentially some of the structured lipids that could come from that area?

Yves Boland
CTO, Corbion

Yeah.

Sebastian Bray
Analyst, Berenberg Bank

First question.

Yves Boland
CTO, Corbion

Okay. I'm not going to comment on specific investment, but the structured lipids development and algae development we are talking about are based on the same technology stack of the one we are already using in DHA. We have the research group. We have an extended strain library with development that we post to focus on DHA development and make sure we could bring it to the market. On that one, I would say that it fits in the current investment, and we're investing selectively when we see opportunities. For the structured lipids, the technology stack is going to be mostly the same.

Sebastian Bray
Analyst, Berenberg Bank

Okay.

Yves Boland
CTO, Corbion

W e have option to produce them in existing asset or even on other type of asset that we have already identified. So, there is not necessarily a need for extra CapEx, especially in the period till 2028, for which we have communicated the CapEx envelope.

Sebastian Bray
Analyst, Berenberg Bank

Yeah. That's helpful. Thank you.

Yves Boland
CTO, Corbion

Awesome.

Robert Jan Vos
Analyst, ABN AMRO

Thank you. Robbie Jan Vos, ABN AMRO. I have two questions. The 18% EBITDA margin objective for 2028, is that based on what you think the current footprint should be at, or is that just a, let's say, first objective for, let's say, in two years' time? My second question, you talked about a lot of stuff in the portfolio. I was wondering, are there still areas where you think, within the portfolio, that do not really fit the current ambitions you have also with innovations and the stuff you showed us today? Are there parts of the portfolio that do not really fit?

Yves Boland
CTO, Corbion

Mm-hmm. So, maybe starting on EBITDA, I will refrain to go in too many financial details, but the target we have announced are for the existing portfolio at constant portfolio, if you like, right, with the visibility on what we have till 2028. That is the first thing. The second thing, I think we have announced our strategy during Capital Markets Day. We are not changing on that.

We see opportunity across the portfolio, some which are more driven by growth, okay, when we can get better margin, and others when we are not really dropping the ball. So, lactic acid remain an important business for us, and we keep on working on the right to operate. The investment we made in Thailand for a circular lactic acid plant is there.

We keep on screening disruptive innovation that can significantly potentially change the production cost without putting a lot of CapEx that would mostly fit into existing manufacturing capabilities. So, those two different type of business, the one which are more growth, the one which are more core, we see potential in both of them. We just approach them differently, and we are not necessarily going to develop a lot of new product, if you like, for the core categories, but we will be focusing more, as we said, on nutrition and preservation for the new product development.

So they have different profile, but we are not dropping the ball. Again, why we are still doing good is because, unlike some other Western company which kept on milking existing asset, Corbion has kept on reinventing itself and being quite bold on some of the technology step which have been made. We have more in the pipeline. We do it in a very, very disciplined manner. But we are not dropping the ball on any of the production line. They have different R&D investment profile and different type of R&D activities. Yep.

Maarten Verbeek
Analyst, The IDEA

Maarten Verbeek , The IDEA . The implementation of your focus, expand, accelerate.

Yves Boland
CTO, Corbion

Yeah.

Maarten Verbeek
Analyst, The IDEA

Has it been fully implemented, i.e., the 3.4 of your R&D to revenue is fully based on this new strategy? Let me put it like that.

Yves Boland
CTO, Corbion

That's a great question. The 3.4 was 2025, and what we've seen is we could get already more from what we have, okay? There is careful plan to grow that, especially as we are generating more growth, and probably in the digital data and AI space as well. That will fit in a slightly increased resource allocation toward R&D. But it's not like we need to double or triple to get where we want to go. Yep.

Maarten Verbeek
Analyst, The IDEA

Secondly, you touched upon it already, the data, digital, and AI. You want to have some 10%-20% efficiency.

Yves Boland
CTO, Corbion

Yep.

Maarten Verbeek
Analyst, The IDEA

How much have you already realized of your target?

Yves Boland
CTO, Corbion

I'm unable to answer that question because what we've seen is the compounded effect of what we have been implementing in terms of more agile innovation processes and focus. We have pocket of implementation, so I cannot give you an exact number. Just by the fact that we see that the speed through the funnel, innovation funnel, is by a factor of four, it means that it's working. I'm unable to delineate. It's an area where we keep on investing in terms of data science and data lab to support that.

Patrick Roquas
Analyst, Kepler Cheuvreux

Patrick Roquas from Kepler Cheuvreux. Two questions. The first one is on the contribution to annual sales growth, which you indicated 1.5%-2%. I assume that's both price and volume, so kind of new ingredients that boost your volume as well as a higher price because of better efficiency or a better quality.

Yves Boland
CTO, Corbion

Yes, so it's new volume at a better margin.

Patrick Roquas
Analyst, Kepler Cheuvreux

Yeah.

Yves Boland
CTO, Corbion

Yeah.

Patrick Roquas
Analyst, Kepler Cheuvreux

On the algae platform, natural colors, is that an area where you see potentially some innovations coming? There's quite some innovation-

Yves Boland
CTO, Corbion

Yeah.

Patrick Roquas
Analyst, Kepler Cheuvreux

... in natural colors coming from algae innovation.

Yves Boland
CTO, Corbion

Depending how you look at it, because you may say that astaxanthin would be a natural color for salmon, but it's mostly for the health benefit. We want to be very disciplined on when we engage, and where we have a right to win. Natural colors, I mean, never say never, but it's not one of our target.

Fernand de Boer
Analyst, Degroof Petercam

Fernand de Boer from Degroof Petercam. On this astaxanthin, could you give a little idea what the price difference is between the synthetic and the natural product?

Yves Boland
CTO, Corbion

It's significant. To compete, I think there might be a factor four, five. The intent is not to compete with synthetic astaxanthin, right? Synthetic astaxanthin is not allowed in food supplement and is not allowed in organic salmon. So, it still leave a sizable market for astaxanthin.

Fernand de Boer
Analyst, Degroof Petercam

What is then the organic salmon market in your view? How big is that?

Yves Boland
CTO, Corbion

It's big enough. I'm not going to give exact number, but we believe it can become a significant.

Fernand de Boer
Analyst, Degroof Petercam

Because if you look entirely at Norway, yeah.

Yves Boland
CTO, Corbion

Yeah.

Fernand de Boer
Analyst, Degroof Petercam

That's not organic. What part then is when is the salmon organic?

Yves Boland
CTO, Corbion

Well, it depends on what you can feed it or not, basically, a nd also, their regulation and customer have their own idea on the topic. The astaxanthin initiative by itself is already worth it for the human nutrition. We scale, we believe we can compete as we scale with organic source of astaxanthin and be more efficient, because customer are reporting challenges with existing sources as well, and they have expressed a clear interest as well to have a reliable high-throughput source of natural astaxanthin.

Fernand de Boer
Analyst, Degroof Petercam

Okay, a nd you team up with BioMar for this one?

Yves Boland
CTO, Corbion

No. We team up with KAS, right?

Fernand de Boer
Analyst, Degroof Petercam

Yeah.

Yves Boland
CTO, Corbion

But for sure, we have an existing customer base on salmon feed, and we are in touch with the various people in the value chain, and we understand very well. So, we are exploring interest there, and we got signal of interest as well.

Fernand de Boer
Analyst, Degroof Petercam

Okay. You mentioned the R&D of innovation expenses of 3.4% sales. If you look at your portfolio, how does that compare with your different competitors?

Yves Boland
CTO, Corbion

Yeah.

Fernand de Boer
Analyst, Degroof Petercam

Everywhere we listen at this moment, everybody's talking about AI and stepping up productivity, et cetera. Competitive speaking, does this really make the difference?

Yves Boland
CTO, Corbion

We need to define who our competitors are because there are some organizations which are closer or have some flavor and fragrance, and they spend significantly higher, or the pure biotech companies, if you like, which sometimes have not even been great at integrating solution. Then we have more the commodity player who actually spend less than us. I do not want to focus on the spend.

What I can tell you is personally, I have been really impressed when I joined Corbion by the technology stack we have versus some other companies. The focus and increasing the hit rate of innovation is really what matters, and where you see a lot of organizations struggling, right, to make sure that what you develop has an impact and you can capture the value on the marketplace.

You can have people spending a lot depending on if you report and not necessarily having an innovation that is hitting a lot. Some of our competitors are more on solution development, but kind of dropped the ball a little bit on developing the new ingredient. What we want to do is really to keep on developing new ingredient because that is the base as well to have profitable solution.

Fernand de Boer
Analyst, Degroof Petercam

Okay. Maybe also simple question, stupid question, I do not know, but how do you determine the winners? Because you said, we are going to focus more on the winners.

Yves Boland
CTO, Corbion

Yeah.

Fernand de Boer
Analyst, Degroof Petercam

Everybody wants to focus on the winners, so how are you sure that you are going to have the right winners and how do you determine then that capacity? In the past, and that's a little bit the issue I have with Corbion, we have seen a lot of products certainly were running quite well. They put a lot of investments, capacity behind it.

Then a few years later, it's off.

Yves Boland
CTO, Corbion

Yeah.

Fernand de Boer
Analyst, Degroof Petercam

Then we had some impairment, et cetera. That's a little bit my feeling.

Yves Boland
CTO, Corbion

Yeah.

Fernand de Boer
Analyst, Degroof Petercam

What is the risk here and how do you identify then now the winners compared to the past?

Yves Boland
CTO, Corbion

We are brutal internally and with the startup we are engaging with, which means that first of all, we are really bringing the two part of the organization, the R&D and the customer-facing and market-facing organization together, and we are relentless in the way we are validating assumptions. That is one thing.

Secondly, if we look at the next platform, we have developed a model and with seven to eight questions, we have our own techno-economical evaluation model, which give us an idea at scale what would be the cost in a relevant location because we operate those operational units. And where people sometime have put effort and faith in strain optimization and machine learning, whatever, to get significant productivity gain, we have directly a view on that, and we merge that with what we understand and also from competitive insight.

We also tend to focus on higher-end market when traceability is important, right? To also try to bring more layers of protection if incumbent, especially from a cheap manufacturing location, wants to enter, a nd if you do that, there are markets when you can do less of that. When you go more to nutrition, that is something that you can do when traceability, country of origin, the whole QC chain that you put in place, the way you potentially also generate health benefit evidence matters and act different layer. We provide different layers of protection. So, we put all of that together.

But we say sometime, we say no after one meeting when we got the data. And again, we have a focus. The example of natural color does not fit, we do not do. Whatever people say, we fit the data in a model, we do not believe it is going to win over time, we do not engage.

Fernand de Boer
Analyst, Degroof Petercam

Thank you.

Reg Watson
Analyst, ING

Reg Watson from ING. I would like to build on the questions that Fernand asked because I think you have shown some impressive gains from innovation and R&D in some of the statistics you have given us. But as Fernand said, other companies are also making leaps and bounds. So, how do you benchmark yourself against your peers? What are the KPIs you are looking at, and what can you share with us in terms of where you feel you are ahead, but also more importantly, I think, where you feel that there is room to catch up?

Yves Boland
CTO, Corbion

Yeah. Great question. We can benchmark looking at revenue from innovation, but everyone report it differently, so it is really complicated. So, what I like to do is to look at how more profitable product from innovation are. Expected the question, so it is about 9% in term of a gross margin versus the rest of the business. So for me, that is an absolute metrics.

I think we are also progressing on how we are integrating solution and capturing value at customer. We have invested in CRM. We see really great adoption, and we have tracking tools, so we are also working on how to best engage with customer and deliver the value to also really focus when we can make a difference again, right? Those are some of the metrics in terms of sales pipeline, which are supported by solution and innovation, the profitability as well of the revenue from innovation are the two main one. Yeah.

Reg Watson
Analyst, ING

Okay, and a quick follow-up because that was my next question, my segue. The opening slide had 20% of products from innovation. I may have missed the footnotes on how that's defined, and you kind of gave the answer to that. Everybody defines it differently, so how do you define it?

Yves Boland
CTO, Corbion

Yeah. Here, it's new product, so product from innovation and product which are also produced through innovative process, because it gives you, especially if they are disruptive, a long-lasting advantage as well versus your competitor. For solution development, basically when you are putting a solution with various ingredients together, we count it for three years.

For incremental innovation, where you have product, you're developing a new product, extending the lineup, not necessarily a new ingredient, we count it for five years. For disruptive innovation, something which is completely new, and new to the world, which has kind of typically a slower adoption curve, we count up to 15 years. Yeah. 15, one, five. The number I showed don't go back that far. The number I showed were more over the last five years.

Reg Watson
Analyst, ING

Okay. Ironically, without knowing the breakdown between innovative, incremental, and disruptive, we can't really work out the turnover and duration of this for the innovation itself.

Yves Boland
CTO, Corbion

Yeah.

Reg Watson
Analyst, ING

Okay. Nice one.

Maarten Verbeek
Analyst, The IDEA

As a follow-up, Maarten again from The IDEA . As a follow-up, could you more or less indicate how much that was, that innovation rate, three years ago, and more or less what you target in three years' time?

Yves Boland
CTO, Corbion

I don't have the number from three years ago. To be honest, I expect significantly lower, because there is a part as well on a lot of it also has to do with what we did in omega-3 DHA, also the work on a new product format, or improved strain and fermentation process and the like count a lot. So, I expect it to grow, but we have quite a lot of other things which are going to contribute to the 1.5%-2%.

Sebastian Bray
Analyst, Berenberg Bank

Thank you. Sebastian Bray of Berenberg again. We haven't talked about timing for any of these innovations, and when do you think the first of them will come to market? So when will Corbion derive astaxanthin, the salmon colorant or the structured lipids, or the new types of natural preservation? Could you give any idea of when these will become available?

Yves Boland
CTO, Corbion

Yes and no. What I want to make clear is, we are tracking the delivery by the end of the strategic period, 2030, right? Some, like natural preservation, some of them were already in test market. Astaxanthin, we are making very good progress, as announced as well by our partner, KAS. But first, in human nutrition, right? As we scale, then it can also go to aqua.

The structured lipids, again, we are doing very good progress, but there is the whole regulatory path that we need to take into account. As you know, in Europe, it tends to be longer than in the U.S. The U.S. was always the first area to launch. There are changes as well on the regulation there on how to introduce a new ingredient to the market, that we believe we can navigate. The next one is likely to be in natural preservation, to be honest.

Sebastian Bray
Analyst, Berenberg Bank

That's helpful. Thank you. Yves, I appreciate this is more a forum for discussing R&D than it is necessarily trading or how things are going, but do you have any comments on, number one, is Olivier retiring at the end of his term? Any comments on where your CEO is going? Number two, how trading more broadly has developed in Q4?

Yves Boland
CTO, Corbion

Thanks for asking the question. Today, I'm focusing on R&D and innovation, so I'm not going to answer those.

Reg Watson
Analyst, ING

Sorry, Reg again. Just going through my notes, I realized that I didn't follow up on where you feel your innovation has room for improvement in your process, what you would like to improve, where you feel you are behind the competition, so there is scope to catch up.

Yves Boland
CTO, Corbion

Yeah. For me, it is really the link between our technology group, and they are amazing at delivering when they know what to deliver, and what the market really wants, right? So developing solution that customer care about, right? And we are great at developing solution, combining stuff. In one hand, we have deep understanding, especially in some market in aqua, meat, bakery, confectionery, of what our customer operation are, and it has not always been trickling down to very sharp, benefit-based innovation.

So we have ended up doing great technical work and focusing on the technical solution, but sometimes the people are actually already designed the solution for the problem, and focusing on how to provide the benefit or solve a problem for a customer instead of just a technology project, I am going to deliver this ingredient, whatever, can make a huge, huge difference. Because then you come with an open mind, you come being technology agnostic, and you come up with the best solution that will really be adopted by customer.

Reg Watson
Analyst, ING

Is that a sales-

Yves Boland
CTO, Corbion

Yeah.

Reg Watson
Analyst, ING

Is that a sales organization issue or an innovation understanding issue?

Yves Boland
CTO, Corbion

Neither. Both are very good at what they do. I think we should make a better link very early in the process. What we do is, I spoke about going faster through the innovation funnel. The one thing we go slower is the scoping stage. Make sure we have the understanding, then we flow it and we accelerate.

Reg Watson
Analyst, ING

Okay, thank you.

Yves Boland
CTO, Corbion

Yeah.

Alex Sokolowski
VP of Investor Relations, Corbion

Thank you. That is going to conclude our webcast this morning. Thank you to everyone online for attending, and thank you for the questions. Until next time, thank you.